NCT05636007 is a clinical trial of Huawei Watch in Hypodlycemia, sponsored by Sun Yat-sen University.

Who is sponsoring NCT05636007?

NCT05636007 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05636007?

Interventions in NCT05636007: Huawei Watch.

What condition does NCT05636007 study?

NCT05636007 studies Hypodlycemia.

Is NCT05636007 still recruiting?

NCT05636007 is currently status unknown. Last updated 2 December 2022.

Last reviewed 2022-12-02 · How we verify

NCT05636007

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Detection of noctUrnal hypoglyCemiA in TypE 2 Diabetes Using Pulse Rate Variability Measured by a Smartwatch(EDUCATED-Smartwatch)

Status unknown Last updated 2 December 2022

What this trial tests

trial testing Huawei Watch in Hypodlycemia in 150 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
1 July 2023

1 August 2023

Quick facts

Lead sponsor	Sun Yat-sen University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 December 2022
Primary completion	1 July 2023
Estimated completion	1 August 2023
Sites	1 location across China

Drugs / interventions tested

Huawei Watch

Conditions studied

Hypodlycemia — all drugs for Hypodlycemia →

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Hypodlycemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In patients with type 2 diabetes, it is necessary to identify and manage nocturnal hypoglycemia as early as possible, so as to reduce the damage caused by nocturnal hypoglycemia.We explore whether smartwatches can provide early warning of nocturnal hypoglycemic events in patients with type 2 diabetes by detecting changes in pulse variability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05636007 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 2 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05636007.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing